Akebia Ther Stock Investor Sentiment

AKBA Stock  USD 2.04  0.09  4.23%   
About 65% of Akebia Ther's investor base is looking to short. The analysis of the overall investor sentiment regarding Akebia Ther suggests that many traders are alarmed. The current market sentiment, together with Akebia Ther's historical and current headlines, can help investors time the market. In addition, many technical investors use Akebia Ther stock news signals to limit their universe of possible portfolio assets.
  

Akebia Ther Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Akebia Ther can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at gurufocus.com         
Akebia Therapeutics Inc Q2 2024 Earnings EPS Misses, Revenue Falls Short at 43.6 Million
Gurufocus Stories at Macroaxis
over three months ago at simplywall.st         
Akebia Therapeutics, Inc. Stock Catapults 34 percent Though Its Price And Business Still Lag The Ind...
Simply Wall St News at Macroaxis
over three months ago at finance.yahoo.com         
Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business High...
Yahoo News
over three months ago at finance.yahoo.com         
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over three months ago at finance.yahoo.com         
Akebia Therapeutics to Present at Upcoming Investor Conferences
Yahoo News
over three months ago at www.macroaxis.com         
Disposition of 6613 shares by Steven Burke of Akebia Ther at 0.8775 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Akebia Therapeutics, Inc. Short Interest Update - American Banking and Market News
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo Tablets
Yahoo News
over three months ago at seekingalpha.com         
Akebia stock gains on full Vafseo rights
seekingalpha News
over three months ago at news.google.com         
Akebia Therapeutics, Inc. Short Interest Update - Defense World
Google News at Macroaxis
over three months ago at benzinga.com         
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
benzinga news
over three months ago at finance.yahoo.com         
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over three months ago at www.macroaxis.com         
Acquisition by Ostrowski Erik of 350000 shares of Akebia Ther subject to Rule 16b-3
Macroaxis News
over three months ago at finance.yahoo.com         
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Yahoo News
over three months ago at finance.yahoo.com         
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
Yahoo News
Far too much social signal, news, headlines, and media speculation about Akebia Ther that are available to investors today. That information is available publicly through Akebia media outlets and privately through word of mouth or via Akebia internal channels. However, regardless of the origin, that massive amount of Akebia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akebia Ther news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akebia Ther relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akebia Ther's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akebia Ther alpha.

Akebia Ther Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo for Patients on Dialysis
10/07/2024
2
CMS Grants TDAPA Reimbursement for Vafseo beginning January 1, 2025
10/10/2024
3
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo for Patients on Dialysis
10/22/2024
4
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
11/01/2024
5
Acquisition by Rogers Michael W of 30000 shares of Akebia Ther subject to Rule 16b-3
11/05/2024
6
Akebia Q3 2024 Earnings Preview
11/06/2024
7
Akebia GAAP EPS of -0.10, revenue of 37.4M
11/07/2024
8
Akebia Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Revenue Challenges ...
11/08/2024
9
Q3 2024 Earnings Hold Akebia Therapeutics - Seeking Alpha
11/20/2024
10
Akebia Therapeutics, Inc. Sees Large Decline in Short Interest
12/02/2024

Complementary Tools for Akebia Stock analysis

When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency